$4.03
+0.18
(+4.68%)▲
5.71%
Downside
Day's Volatility :6.63%
Upside
0.98%
51.91%
Downside
52 Weeks Volatility :52.38%
Upside
0.98%
Period | Diamedica Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | 57.42% | 0.0% |
6 Months | 31.27% | 0.0% |
1 Year | 21.02% | 0.0% |
3 Years | -4.05% | -22.3% |
Market Capitalization | 169.3M |
Book Value | $1.25 |
Earnings Per Share (EPS) | -0.51 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -23.54% |
Return On Equity TTM | -35.18% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -22.4M |
Diluted Eps TTM | -0.51 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.62 |
EPS Estimate Next Year | -0.76 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | -0.16 |
What analysts predicted
Upside of 73.7%
Sell
Neutral
Buy
Diamedica Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Diamedica Therapeutics Inc | 24.0% | 31.27% | 21.02% | -4.05% | 44.44% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Diamedica Therapeutics Inc | NA | NA | NA | -0.62 | -0.35 | -0.24 | NA | 1.25 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Diamedica Therapeutics Inc | Buy | $169.3M | 44.44% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Diamedica Therapeutics Inc
Revenue is up for the last 3 quarters, 13.0K → 30.83M (in $), with an average increase of 91.3% per quarter
Netprofit is up for the last 3 quarters, -5.16M → -5.11M (in $), with an average increase of 0.4% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 16.1%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 73.2%
Cooperman Leon G
Vanguard Group Inc
First Manhattan Co. LLC
PARAGON Assoc & PARAGON Assoc II JV
Bleichroeder LP
Geode Capital Management, LLC
diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.
Organization | Diamedica Therapeutics Inc |
Employees | 18 |
CEO | Mr. Dietrich John Pauls MBA |
Industry | Health Technology |
A Spac I Acquisition Corp
$4.03
+4.68%
Keyarch Acquisition Corp
$4.03
+4.68%
Connexa Sports Technologies Inc
$4.03
+4.68%
Us Value Etf
$4.03
+4.68%
First Wave Biopharma Inc
$4.03
+4.68%
Global X Msci Next Emerging
$4.03
+4.68%
Fat Projects Acquisition Corp
$4.03
+4.68%
Capital Link Global Fintech
$4.03
+4.68%
Applied Uv Inc
$4.03
+4.68%